Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53.

Autor: Hernandez Borrero L; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, The Warren Alpert Medical School, Brown University, Providence, United States.; The Joint Program in Cancer Biology, Brown University and the Lifespan Health System, Providence, United States.; Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, United States.; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, United States.; Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, United States., Dicker DT; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, The Warren Alpert Medical School, Brown University, Providence, United States.; The Joint Program in Cancer Biology, Brown University and the Lifespan Health System, Providence, United States.; Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, United States.; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, United States.; Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, United States., Santiago J; Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, United States., Sanders J; The Joint Program in Cancer Biology, Brown University and the Lifespan Health System, Providence, United States.; Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, United States.; Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, United States.; Department of Pediatrics, The Warren Alpert Medical School, Brown University, Providence, United States., Tian X; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, The Warren Alpert Medical School, Brown University, Providence, United States.; The Joint Program in Cancer Biology, Brown University and the Lifespan Health System, Providence, United States.; Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, United States.; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, United States.; Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, United States., Ahsan N; COBRE Center for Cancer Research Development, Proteomics Core Facility, Rhode Island Hospital, Providence, United States., Lev A; The Joint Program in Cancer Biology, Brown University and the Lifespan Health System, Providence, United States.; Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, United States.; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, United States., Zhou L; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, The Warren Alpert Medical School, Brown University, Providence, United States.; The Joint Program in Cancer Biology, Brown University and the Lifespan Health System, Providence, United States.; Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, United States.; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, United States.; Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, United States., El-Deiry WS; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, The Warren Alpert Medical School, Brown University, Providence, United States.; The Joint Program in Cancer Biology, Brown University and the Lifespan Health System, Providence, United States.; Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, United States.; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, United States.; Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, United States.; Hematology-Oncology Division, Department of Medicine, Rhode Island Hospital and Brown University, Providence, United States.

Publikováno v: ELife [Elife] 2021 Jul 29; Vol. 10. Date of Electronic Publication: 2021 Jul 29.

Author response: A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53

Autor: Liz Hernandez Borrero, David T Dicker, John Santiago, Jennifer Sanders, Xiaobing Tian, Nagib Ahsan, Avital Lev, Lanlan Zhou, Wafik S El-Deiry

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ef7354591747615fbcc9e41592eb5ef
https://doi.org/10.7554/elife.70429.sa2

Induction of a caffeine-sensitive S-phase cell cycle checkpoint by psoralen plus ultraviolet A radiation.

Autor: Joerges, Christoph¹, Kuntze, Inge¹, Herzinge, Thomas¹ Thomas.Herzinger@lrz.uni-muenchen.de

Publikováno v: Oncogene. 9/18/2003, Vol. 22 Issue 40, p6119-6128. 10p. 4 Diagrams, 5 Graphs.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.